• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

MOCETINOSTAT Drug Record

  • Summary
  • Interactions
  • Claims
  • MOCETINOSTAT chembl:CHEMBL272980 Antineoplastic

    Alternate Names:

    MGCD0103
    MOCETINOSTAT
    MGCD-0103
    chembl:CHEMBL272980
    chemidplus:726169-73-9
    pubchem.compound:9865515
    drugbank:11830

    Drug Info:

    FDA Approval not approved
    Drug Class Small molecule
    Drug Indications antineoplastic agent
    (2 More Sources)

    Publications:

    Marson CM et al., 2015, Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit., J Med Chem
    Marson CM et al., 2013, Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit., J Med Chem
    Khan et al., 2008, Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors., Biochem. J.
    Beckers et al., 2007, Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group., Int. J. Cancer
    Cruickshank et al., 2017, Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin., Leukemia
  • MOCETINOSTAT   HDAC1

    Interaction Score: 0.81

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name MGCD-0103
    Novel drug target Established target
    Mechanism of Interaction Histone deacetylase 1 inhibitor

    PMIDs:
    26287310 23829483 17455259 17868033


    Sources:
    DTC TdgClinicalTrial ChemblInteractions TTD

  • MOCETINOSTAT   HDAC11

    Interaction Score: 0.79

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name MGCD-0103
    Novel drug target Established target
    Mechanism of Interaction Histone deacetylase 11

    PMIDs:
    26287310 23829483


    Sources:
    DTC TdgClinicalTrial ChemblInteractions

  • MOCETINOSTAT   HDAC3

    Interaction Score: 0.75

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Histone deacetylase 3
    Trial Name MGCD-0103

    PMIDs:
    26287310 23829483 17455259


    Sources:
    DTC TdgClinicalTrial ChemblInteractions

  • MOCETINOSTAT   HDAC2

    Interaction Score: 0.73

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name MGCD-0103
    Novel drug target Established target
    Mechanism of Interaction Histone deacetylase 2 inhibitor

    PMIDs:
    17868033 26287310 23829483


    Sources:
    DTC TdgClinicalTrial ChemblInteractions

  • MOCETINOSTAT   HDAC8

    Interaction Score: 0.64

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name MGCD-0103
    Novel drug target Established target
    Mechanism of Interaction Histone deacetylase 8 inhibitor

    PMIDs:
    26287310 23829483


    Sources:
    DTC TdgClinicalTrial ChemblInteractions

  • MOCETINOSTAT   HDAC9

    Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name MGCD-0103
    Novel drug target Established target

    PMIDs:
    26287310 23829483


    Sources:
    DTC TdgClinicalTrial

  • MOCETINOSTAT   HDAC10

    Interaction Score: 0.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name MGCD-0103
    Novel drug target Established target

    PMIDs:
    26287310 23829483


    Sources:
    DTC TdgClinicalTrial

  • MOCETINOSTAT   HDAC7

    Interaction Score: 0.54

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name MGCD-0103
    Novel drug target Established target

    PMIDs:
    26287310 23829483


    Sources:
    DTC TdgClinicalTrial

  • MOCETINOSTAT   HDAC5

    Interaction Score: 0.54

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name MGCD-0103
    Novel drug target Established target

    PMIDs:
    26287310 23829483


    Sources:
    DTC TdgClinicalTrial

  • MOCETINOSTAT   HDAC4

    Interaction Score: 0.49

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Novel drug target Established target
    Trial Name MGCD-0103

    PMIDs:
    26287310 23829483


    Sources:
    DTC TdgClinicalTrial

  • MOCETINOSTAT   HDAC6

    Interaction Score: 0.49

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name MGCD-0103
    Novel drug target Established target

    PMIDs:
    26287310 23829483


    Sources:
    DTC TdgClinicalTrial

  • MOCETINOSTAT   KMT2A

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cytarabine + Mocetinostat
    Indication/Tumor Type acute lymphocytic leukemia
    Response Type sensitive

    PMIDs:
    27443263


    Sources:
    JAX-CKB

  • MOCETINOSTAT   HTT

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • TdgClinicalTrial: MGCD-0103

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small molecule
    FDA Approval not approved

    Publications:

  • DTC: MOCETINOSTAT

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL272980 ChEMBL Drug ID

    Drug Info:

    Publications:
    Marson CM et al., 2013, Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit., J Med Chem
    Marson CM et al., 2015, Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit., J Med Chem

  • JAX-CKB: Mocetinostat

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Cruickshank et al., 2017, Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin., Leukemia

  • TTD: MGCD-0103

    • Version: 2020.06.01

    Alternate Names:
    D00FHR TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL272980

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL272980

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21